GSK's share price fall on results day did nothing to change its dividend plans, but it did change the arithmetic of the yield that income-focused investors see.

For many holders of FTSE 100 shares, the dividend is the main attraction, and the payout from GSK (LSE:GSK) is a natural point of focus for that audience. Its third-quarter results on Wednesday 28 October 2026 confirmed a 17p dividend for the quarter and an expected 70p for the full year 2026. The same day, the shares fell 4.78% to 1,831.50p, as investors reacted to a weaker-than-expected vaccines contribution and doubts about the company's pipeline-building push.

The combination of a steady dividend and a lower share price raises a straightforward question: what does GSK's payout look like for someone weighing it as an income stream?

The payout in numbers

GSK declared a third-quarter dividend of 17p per share and said it expects to pay 70p in total for 2026. The word "expects" matters. A stated expectation is not the same as a commitment, and dividends are decided by a company's board in light of its earnings, cash flows and priorities at the time.

The material reviewed here does not give the ex-dividend or payment dates for the third-quarter dividend, so investors looking for those details would need to consult GSK's own announcements.

How the share price fall changes the yield

Dividend yield expresses the annual dividend as a % of the share price. Because the price moves every day while the dividend is fixed for long periods, the yield shifts as the shares rise and fall.

Ahead of the results, GSK's dividend yield was 3.6% and the shares had risen 27% over two years. The exact basis of that yield figure is not set out in the material reviewed here.

A higher yield after a price fall can look attractive on paper, but it is worth remembering why the price fell. A yield rises mechanically when a share price drops, and that drop may reflect concerns about the business that could, in time, affect the dividend.

Can earnings support the payout?

One way investors judge dividend sustainability is by comparing earnings with the amount paid out, a ratio often called dividend cover. A higher cover means more profit is retained after paying the dividend.

GSK reported third-quarter core earnings per share of 54.6p, up 1% at constant exchange rates, and total earnings per share of 38.5p, down 21% at constant exchange rates. Core earnings of 54.6p were roughly 3.2 times the 17p quarterly dividend, while total earnings of 38.5p were roughly 2.3 times. A single quarter is a narrow basis for judging cover, and the two earnings measures differ because total earnings include items that core figures exclude.

The company also reaffirmed its 2026 guidance at constant exchange rates: turnover growth of 3–5%, in the upper half of that range; core operating profit growth of 7–9%, in the upper half; and core earnings per share growth of 7–9%, in the lower half. Guidance of this kind is relevant to income investors because earnings growth gives a board more room to maintain or raise payouts.

Chief executive Luke Miels said GSK had delivered another good quarter.

GSK's £2bn share buyback, announced in FY2024, was completed in the second quarter of 2026, and no new buyback was announced alongside the third-quarter results. For shareholders, that means the dividend is currently the main channel through which GSK returns cash.

The company is also funding its Accelerate Growth programme, which aims to deliver £1.9bn of annual savings by 2029, with expected total costs of £2.4bn, as well as a heavy pipeline schedule. It has made 18 of the 22 phase III starts it planned for 2026. Investment of that scale competes with distributions for cash, and how GSK balances the two over time is something income investors are likely to monitor.

The quarter's divisional performance adds context. Specialty Medicines grew 15% at CER to £3.9bn, while vaccines fell 2% to £2.6bn, with Shingrix down 5% at £0.8bn. General Medicines was broadly stable at £2.4bn.

GSK's fall came on a day when the FTSE 100 rose just 7.96 points to 10,694.50. Market reports said that personal care, drug and grocery stocks fell nearly 1.4%, with Unilever (LSE:ULVR) down 2.05% after its own trading update. In the Budget, the annual cash ISA limit stayed at £20,000, leaving one element of the savings landscape unchanged.

Key dates to watch

  • Fri 30 Oct 2026: AstraZeneca (LSE:AZN) reports Q3 results, offering a comparison for pharma sentiment and capital returns.
  • Thu 5 Nov 2026: The Bank of England MPC decision and Monetary Policy Report, which can influence how dividend yields compare with interest rates.
  • Thu 12 Nov 2026: Unilever goes ex-dividend, another FTSE 100 income date this quarter.
  • Wed 2 Dec 2026: The FTSE December review announcement after the close.
  • Thu 17 Dec 2026: The Bank of England's final rate decision of the year.

The bottom line

GSK's 17p third-quarter dividend and its expectation of 70p for 2026 were unaffected by Wednesday's share price fall, but the yield implied by those figures rose as the shares dropped to 1,831.50p. Earnings for the quarter comfortably exceeded the quarterly payout on both core and total measures, and guidance was reaffirmed. Against that, the buyback has ended without a successor, and the business is investing heavily in restructuring and its pipeline. For income seekers, the dividend plan is clear; the factors that will shape it over time are still unfolding.